Latest Administration News

LTR Pharma has expanded patient access to its fast-acting erectile dysfunction treatment SPONTAN by partnering with TerryWhite Chemmart’s extensive pharmacy network, marking a significant step in its commercial rollout and regulatory strategy.

Lumos Diagnostics has secured Medicare reimbursement for its FebriDx test from a fifth contractor, covering more than 70% of US Medicare payments and advancing its commercial reach.

State Street Global Advisors announces key updates to its SPDR Fixed Income ETFs, including a significant fee reduction for the Australian Bond ETF and a rebranding to incorporate the iBoxx index name, effective June 2025.

Anson Resources has negotiated a pioneering scaled royalty structure for its Green River Lithium Project in Utah, reducing the previous flat 5% rate to a sliding scale tied to lithium prices. This move enhances project viability and investment certainty amid evolving regulatory reforms.

Almonty Industries reports steady tungsten market conditions and completes key financing for its Sangdong Mine, while posting a $34.6 million net loss in Q1 2025. The company advances its US Domestication and plans to restart Los Santos Mine in 2026.

Cynata Therapeutics confirms that the recent FDA orphan-drug exclusivity granted to Ryoncil® will not block approval of its CYP-001 therapy, highlighting key differences in drug composition and patient indications.

Field Solutions Group has executed a binding agreement to sell its TasmaNet business to Comms Group Ltd as part of its receivership process, with further asset sales underway.

The Finnish Government’s proposed amendments to the Mining Act could resolve licensing uncertainties for Latitude 66’s KSB Project, even as key mining rights expire following a court decision.

Comms Group Limited announces a strategic $10 million acquisition of TasmaNet and select assets from Field Solutions Holdings, alongside a $7 million capital raise, targeting a proforma FY25 revenue of approximately $75 million.

Classic Minerals Limited has announced the resignation of CEO Dean Goodwin, effective April 7, 2025, with Chair John Lester stepping in as interim leader. The delayed disclosure raises questions about governance timing.

Mesoblast has been granted a seven-year orphan-drug exclusivity by the FDA for its cell therapy Ryoncil, reinforcing its market position in treating steroid-refractory acute graft versus host disease in children.

NRW Holdings faces a significant threat to its $113.3 million secured debt after the South Australian Government proposed legislation that could invalidate key lease agreements underpinning its security interests in Whyalla Ports.